Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-07-01
2008-07-01
Rao, Manjunath (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S134100, C424S143100, C424S154100, C424S133100, C424S178100, C435S377000
Reexamination Certificate
active
10088950
ABSTRACT:
The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.
REFERENCES:
patent: 4275149 (1981-06-01), Litman et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681722 (1997-10-01), Newman et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5756096 (1998-05-01), Newman et al.
patent: 5792850 (1998-08-01), Baumgartner et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5925735 (1999-07-01), Baumgartner et al.
patent: 6080406 (2000-06-01), Baumgartner et al.
patent: 6323027 (2001-11-01), Burkly et al.
patent: 2004/0219096 (2004-11-01), De Waal Malefyt et al.
patent: 2004/0234522 (2004-11-01), DeSauvage et al.
patent: 2005/0164307 (2005-07-01), Kojima et al.
patent: WO 97/44455 (1997-11-01), None
patent: WO 99/41095 (1999-08-01), None
patent: WO 00/28827 (2000-10-01), None
Lewis (2002), Curr. Opin. Immun. 14: 644-651.
Lucas et al., (Proc Natl. Acad. Sci. U S A. Dec. 9, 2003; 100(25):15047-52).
Altschul et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs”Nucleic Acids Research, 25(17):3389-3402 (1997).
Bazan, J., “Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily”Proc. Natl. Acad. Sci. USA87:6934-6938 (1990).
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”The Journal of Immunology147(1):86-95 (1991).
Bolton, C., “Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment.”Multiple Sclerosis, 1:143-149 (1995).
Carter et al., “Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors”Nucl. Acids Res. 13(12):4431-4443 (Jun. 25, 1985).
Chambers and Allison., “Co-Stimulation in T Cell Responses.”Current Opinion in Immunology, 9(3):396-404 (Jun. 1997).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries”Nature352:624-628 (1991).
Cole et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer”Monoclonal Antibodies and Cancer Therapy, New York:Alan R. Liss, Inc. pp. 77-96 (1985).
Constant, S.L. et al., “Induction of Th1 and Th2 CD4+ T Cell Responses: The alternative approaches”Annual Review of Immunology15:297-322 (1997).
Cosman, D., “The Hematopoietin Receptor Superfamily”Cytokine5(2):95-106 (Mar. 1993).
Finn and Lotze., “Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer.”Journal of Immunotherapy, 21(2):114-118 (Mar. 1998).
Fishwild et al., “High-Avidity Human IgGk Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice”Nature Biotechnology, 14(7):845-851 (Jul. 1996).
Heid et al., “Real time quantitative PCR”Genome Research6(10):986-994 (1996).
Hoogenboom and Winter, “By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline VHGene Segments Rearranged in Vitro”J. Mol. Biol.227:381-388 (1992).
Hsieh, C.S. et al., “Development of TH1 CD4+T Cells Through IL-12 Produced by Listeria-Induced Macrophages”Science260:547-549 (1993).
Jenkins, M., “The Ups and Downs of T Cell Costimulation.”Immunity, 1(6):443-446 (Sep. 1994).
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse”Nature321:522-525 (May 29, 1986).
June et al., “The B7 and CD28 Receptor Families.”Immunology Today, 15(7):321-331 (Jul. 1994).
Kaplan, M. H. et al., “Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice”Nature382:174-177 (1996).
Kohler, G. and Milstein, C., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”Nature256:495-497 (Aug. 7, 1975).
Kuhn, R. et al., “Generation and analysis of interleukin-4 deficient mice”Science254:707-710 (1991).
Kwon et al., “Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer.”Proc. Natl. Acad. Sci. USA94(15):8099-8103 (Jul. 22, 1997).
Le Gros, G. et al., “Generation of Interleukin 4 (IL-4) -producing Cells In Vivo and In Vitro: IL-2 and IL-4 Are Required For In Vivo Generation of IL-4-producing Cells”Journal of Experimental Medicine172:921-929 (1990).
Linsley and Ledbetter., “The Role of the CD28 Receptor During T Cell Responses to Antigen.”Annu. Rev. Immunol.11:191-212 (1993).
Lonberg and Huszar., “Human Antibodies From Transgenic Mice”International Reviews of Immunology13(1):65-93 (1995).
Lonberg et al., “Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications”Nature. 368(6474):856-859 (Apr. 28, 1994).
Lynch et al., “Flt3 Ligand Induces Tumor Regression and Antitumor Immune Responses In Vivo.”Nature Medicine, 3(6):625-631 (Jun. 1997).
Magram, J. et al., “IL-12-deficient mice are defective in IFNγ production and type 1 cytokine responses”Immunity4:471-481 (1996).
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”Bio/Technology10:779-783 (1992).
Marks et al., “By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage”J. Mol. Biol.222:581-597 (1991).
Melero et al., “Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors.”Nature Medicine, 3(6):682-685 (Jun. 1997).
Morrison, S., “Immunology: Success in Specification”Nature. 368(6474):812-813 (Apr. 28, 1994).
Neuberger, M., “Generating High-Avidity Human Mabs in Mice”Nature Biotechnology, 14(7):826 (Jul. 1996).
Noben-Trauth, N. et al., “An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice”Proc. Natl. Acad. Sci. USA94:10838-10843 (1997).
O'Garra, A., “Cytokines induce the development of functionally heterogeneous T helper cell subsets”Immunity8:275-283 (1998).
Presta, L., “Antibody Engineering”Curr. Op. Struct. Biol.2:593-596 (1992).
Riechmann et al., “Reshaping Human Antibodies for Therapy”Nature332:323-327 (Mar. 24, 1988).
Romagnani, S. et al., “Human Th1 and Th2 cells: functional properties, mechanisms of development and role in diseases”Allergologie, Muenchen-DeisenhDE:Dustri Verlag vol. 18(4):175-179 (1996).
Schwartz, R., “Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy.”Cell. 71(7):1065-1068 (Dec. 24, 1992).
Seder, R.A. et al., “Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming”Proc. Natl. Acad. Sci. USA90:10188-10192 (1993).
Shimoda, K. et al., “Lack of IL-4-induce
de Sauvage Frederic J.
Grewal Iqbal
Gurney Austin L.
Gamett Daniel C
Genentech Inc.
Morrison & Foerster / LLP
Rao Manjunath
LandOfFree
Modulation of T cell differentiation for the treatment of T... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of T cell differentiation for the treatment of T..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of T cell differentiation for the treatment of T... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3957596